There are 2789 resources available
Q&A and live discussion
Presenter: Maurice Pérol
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Lyudmila Bazhenova
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Slides
Webcast
Invited Discussant 1501O_PR and 1502O
Presenter: Olga Husson
Session: Proffered Paper session - Public policy
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Eleni Efstathiou
Session: Enhanced androgen signalling inhibition should be the treatment of choice for treatment of mCSPC rather than docetaxel
Resources:
Slides
Webcast
Yes
Presenter: Karim Fizazi
Session: Enhanced androgen signalling inhibition should be the treatment of choice for treatment of mCSPC rather than docetaxel
Resources:
Slides
Webcast
No
Presenter: Ronald De Wit
Session: Enhanced androgen signalling inhibition should be the treatment of choice for treatment of mCSPC rather than docetaxel
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Eleni Efstathiou
Session: Enhanced androgen signalling inhibition should be the treatment of choice for treatment of mCSPC rather than docetaxel
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Lena Specht
Session: Proffered Paper session - Haematological malignancies
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Lisa Licitra
Session: Proffered Paper session - Head and neck cancer, excl. thyroid
Resources:
Slides
Webcast
Invited Discussant LBA47 and 1281O
Presenter: Lyudmila Bazhenova
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Slides
Webcast